Core Viewpoint - The article discusses the competitive landscape of the weight loss drug market, highlighting the significant price reductions expected with the inclusion of Eli Lilly's drug, tirzepatide, into the medical insurance system, which is anticipated to lead to a price drop of up to 80% [4][6]. Group 1: Market Dynamics - The weight loss drug market is experiencing intense competition, with multinational companies engaging in a "price war" as they seek to capture market share [3]. - Tirzepatide's price will be significantly reduced starting January 1, with specific prices listed for various dosages, indicating a shift towards more affordable options for consumers [4][5]. - Novo Nordisk's weight loss drug, semaglutide, is also expected to see a price reduction of nearly 50%, further intensifying the competitive pricing environment [6]. Group 2: Consumer Behavior - The decision-making process for patients has shifted from post-consultation to pre-consultation, with many seeking prescriptions for weight loss drugs before visiting healthcare providers [8]. - The market for weight loss drugs is becoming increasingly consumer-driven, with patients actively seeking these medications, akin to purchasing consumer electronics [9]. - Data from e-commerce platforms indicate a significant gender and age disparity in the consumer base, with women making up about three times the number of male users and 85% of buyers being under 40 years old [10]. Group 3: Future Outlook - The global weight loss drug market is projected to grow to approximately $150 billion over the next decade, indicating a trend towards these medications becoming a part of everyday lifestyle choices [10]. - The potential for direct-to-consumer sales of weight loss drugs raises concerns about safety and regulation, as bypassing traditional healthcare systems could lead to risks associated with side effects and long-term health implications [10].

第一财经记者注意到，在南京鼓楼医院公众号上，该院减重代谢中心称，自明年1月1日起，替尔泊肽 将"大降价"，具体价格为2.5mg*4次324.1元；5.0mg*4次551元；7.5mg*4次751元；10mg*4次936.7元。 以上剂量为每周一次注射。 药企对待这些减重药物的态度，就像在告诉消费者"你现在可以像买一个智能手机那样去买药。"互联网 医疗平台也成为减重药厂商的下一个"竞技场"。 基于大量的用户数据，互联网电商平台正在成为减重药企重要的合作伙伴。第一财经记者刚刚在某互联 网平台上查询相关减重药的信息，就立马收到短信广告："别让肚腩负担毁了旅行，露腰自由自信站C 位！"后面附有某国内减重药厂商的产品购买链接。 这就是减重药市场的竞争现状。跨国巨头也在积极投身这场难以避免的"价格战"。礼来的减重药替尔泊 肽纳入医保后，价格也将"大跳水"。 礼来减重药价格"大跳水" 明年1月1日起，礼来公司的重磅减重药替尔泊肽（商品名：穆峰达）即将纳入医保。近日，已有医院相 关科室公开了1月1日起替尔泊肽的价格。 与此同时，诺和诺德的重磅减重药司美格鲁肽的价格预计也将出现下调。根据四川省药械招采中心近日 公示的一批药品降 ...